- Home
- DTST vs ANTX Comparison
DTST vs ANTX Comparison
Compare DTST & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- ANTX
- Stock Information
- Founded
- DTST 2001
- ANTX 2017
- Country
- DTST United States
- ANTX United States
- Employees
- DTST N/A
- ANTX N/A
- Industry
- DTST EDP Services
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- DTST Technology
- ANTX Health Care
- Exchange
- DTST Nasdaq
- ANTX Nasdaq
- Market Cap
- DTST 32.7M
- ANTX 37.6M
- IPO Year
- DTST N/A
- ANTX 2022
- Fundamental
- Price
- DTST $3.47
- ANTX $1.41
- Analyst Decision
- DTST
- ANTX Hold
- Analyst Count
- DTST 0
- ANTX 5
- Target Price
- DTST N/A
- ANTX $3.50
- AVG Volume (30 Days)
- DTST 33.6K
- ANTX 168.1K
- Earning Date
- DTST 03-27-2025
- ANTX 03-27-2025
- Dividend Yield
- DTST N/A
- ANTX N/A
- EPS Growth
- DTST N/A
- ANTX N/A
- EPS
- DTST 0.02
- ANTX N/A
- Revenue
- DTST $25,143,911.00
- ANTX N/A
- Revenue This Year
- DTST $2.57
- ANTX N/A
- Revenue Next Year
- DTST $11.16
- ANTX N/A
- P/E Ratio
- DTST $172.37
- ANTX N/A
- Revenue Growth
- DTST 1.64
- ANTX N/A
- 52 Week Low
- DTST $3.24
- ANTX $0.87
- 52 Week High
- DTST $8.00
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- DTST 36.06
- ANTX 72.16
- Support Level
- DTST $3.40
- ANTX $1.09
- Resistance Level
- DTST $3.64
- ANTX $1.39
- Average True Range (ATR)
- DTST 0.22
- ANTX 0.06
- MACD
- DTST -0.02
- ANTX 0.03
- Stochastic Oscillator
- DTST 15.63
- ANTX 94.20
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; Flagship Solutions, LLC and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.